Literature DB >> 3674850

In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).

D L Van Caekenberghe1, J Breyssens.   

Abstract

The in vitro interactions between bismuth subcitrate and a variety of antimicrobial agents against 12 Campylobacter pyloridis (C. pylori) isolates were studied by the agar dilution checkerboard technique. The combination of bismuth subcitrate with the older quinolone, oxolinic acid, produced synergistic activity against all strains. This observation, however, could not be extended to the (aryl) fluoroquinolones, norfloxacin, ofloxacin, and difloxacin, since synergy was rare or absent when bismuth subcitrate was combined with these antibiotics. Among the other antimicrobial agents tested, rifampin and the beta-lactams frequently showed showed MICs for C. pyloridis similar to those of bismuth subcitrate.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3674850      PMCID： PMC174956          DOI： 10.1128/AAC.31.9.1429

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  [Nitrofurans: mode of action (author's transl)].

Authors:  A M Gounot; C Brevet; S Videz
Journal:  Ann Pharm Fr       Date:  1979

2.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

3.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors:  C A McNulty; J Dent; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

4.  Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents.

Authors:  T Lambert; F Mégraud; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Campylobacter pyloridis and gastritis.

Authors:  B J Marshall
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

6.  Reversed incomplete cross-resistance among the older and newer quinolone antibiotics.

Authors:  D L van Caekenberghe; S R Pattyn
Journal:  J Antimicrob Chemother       Date:  1987-03       Impact factor: 5.790

7.  [The Campylobacter pyloridis story].

Authors:  G N Tytgat
Journal:  Ned Tijdschr Geneeskd       Date:  1986-03-08

8.  The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors:  C S Goodwin; P Blake; E Blincow
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790
  8 in total
  15 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.

Authors:  T Alarcón; D Domingo; I Sánchez; F Díaz de Rojas; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

3.  Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

Authors:  A E Simor; S Ferro; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 4.  Campylobacter pylori and gastroduodenal disease.

Authors:  G E Buck
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

5.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

6.  In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.

Authors:  J M Meyer; S Ryu; S L Pendland; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate.

Authors:  T O'Riordan; E Mathai; E Tobin; D McKenna; C Keane; E Sweeney; C O'Morain
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

8.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

Authors:  K Nagata; H Satoh; T Iwahi; T Shimoyama; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.

Authors:  D J Muñoz; C Tasman-Jones; J Pybus
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

10.  Evaluation of a rapid urease test to detect Campylobacter pylori infection.

Authors:  T U Westblom; E Madan; J Kemp; M A Subik
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.